Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571330 | 0.89 | MAPT (0.49) | MAPTNPC1RAB9APRKCIHSD17B1 | |
| Hydrochloric Acid SCHEMBL6574158 | 0.88 | MAPT (0.47) | MAPTNPC1RAB9APRKCIHSD17B1 | |
| SCHEMBL3788518 | 0.86 | MAPT (0.55) | MAPTNPC1RAB9APRKCICREBBP | |
| SCHEMBL3790376 | 0.86 | PRKCI (0.50) | MAPTNPC1RAB9APRKCIHSD17B1 | |
| Hydrochloric Acid SCHEMBL27318044 | 0.84 | MAPT (0.53) | MAPTPRKCICREBBPHDAC2S100A4 | |
| SCHEMBL3786947 | 0.84 | PARP10 (0.47) | RELA | |
| SCHEMBL27751282 | 0.83 | SYK (0.54) | NPC1HDAC2SMN1; SMN2RELASYK | |
| SCHEMBL3785416 | 0.81 | FYN (0.45) | MAPTNPC1PRKCICREBBPHDAC2 | |
| SCHEMBL2787158 | 0.80 | SYK (0.51) | MAPTNPC1RAB9ACREBBPSYK | |
| SCHEMBL6011398 | 0.79 | HSD17B1 (0.51) | MAPTNPC1RAB9APRKCIHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885NPC1 724/4885RAB9A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.